Deep Brain Stimulation Systems Market, By Product Type (Single-channel Deep Brain Stimulator and Dual-channel Deep Brain Stimulator), By Application (Parkinson's Disease, Essential Tremor, Obsessive Compulsive Disorder, Epilepsy, Dystonia, and Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Neurological Clinics, and Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI414620 | Publish Date: May 2024 | No. of Pages: 170

Global Deep Brain Stimulation Systems Market Companies

  • Beijing PINS Medical Co. Ltd.
  • Boston Scientific Corporation
  • Fisher Wallace
  • Functional Neuromodulation Ltd.
  • Medtronic PLC
  • NeuroPace Inc.
  • Renishaw PLC.

Recent News:

  • The world leader in medical technology, Medtronic plc, introduced the "SenSightTM" Directional Lead System, and the FDA authorized its first U.S. implants for the device in June 2021. Medical professionals can precisely administer patient-specific DBS therapy for the treatment of certain symptoms related to movement disorders, such as Parkinson's disease, dystonia, and essential tremor, as well as medically refractory epilepsy, with SenSightTM, the first-of-its-kind DBS directional lead that combines the power of sensing with the advantages of directionality.
  • The "InfinityTM" Deep Brain Stimulation (DBS) system, introduced by Abbott, a publicly traded business that develops ground-breaking technologies in the fields of diagnostics, medical equipment, nutrition, and branded generic medications, received FDA approval in January 2020. The internal globus pallidus (GPi) is one of the brain regions targeted by the InfinityTM Deep Brain Stimulation (DBS) technology. As of right now, the only directional DBS system approved to treat essential tremor, Parkinson's disease, and movement disorders is the Infinity DBS system.